Global Cephalosporin Drugs Market Size

Cephalosporin Drugs Market Analysis

The cephalosporin drugs market is expected to grow at registering a CAGR of 2.75% during the forecast period (2022-2027).

The cephalosporin market was damaged by COVID-19's effects on the pharmaceutical industry's worldwide supply chain. However, numerous antibiotics are currently explored and extensively used as a COVID-19 treatment after being initially used to treat COVID-19. Various studies have found that the higher cephalosporin consumption rate and use ratio have made lower morbidity and mortality caused by COVID-19 than another antibacterial. For instance, a research study titled "Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study" published in the PLOS ONE Journal in May 2021, Ceftaroline Fosamil, a cephalosporin antibiotic, has been proposed as a powerful inhibitor of SARS-primary CoV-2's protease responsible for processing the polyprotein translated from viral RNA. Cephalosporin has been widely used to prevent secondary bacterial infection. Also, the cephalosporins in combinations with macrolides and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore, there are in vitro and in vivo studies going on to evaluate the potential of generations of cephalosporin for COVID-19. As a result, the COVID-19 market had a significant influence and is anticipated to grow over the coming years.

The market is expected to grow due to the increasing demand for anti-microbials in various indications, the rising prevalence of infectious diseases such as HIV and tuberculosis, and the increase in funding for the development of antibiotics. For instance, according to the October 2021 report of the World Health Organization, tuberculosis is present in all countries and all age groups, and approximately 10 million people fell ill with tuberculosis (TB) all over the world in 2020, of which eight countries account for two-thirds of the total TB cases in 2021, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. It has also been reported that there is a rapid spread of various infectious diseases that is fueling market growth. Moreover, according to a survey conducted by the World Health Organization for the period from 24 January 2022 to 06 February 2022, approximately 12,368 people were positive for influenza viruses. Out of these, 8,423 (68.1%) people were typed as influenza A and 3,945 (31.9%) people as influenza B. Furthermore, 171 (6.4%) were influenza A (H1N1), and 2,483 (93.6%) were influenza A (H3N2). Thus, the growing burden of infectious diseases is expected to increase the demand for cephalosporin, thereby driving the market growth. The market growth is also attributed to the increase in consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.

Over the forecast period, the market for cephalosporin pharmaceuticals is anticipated to grow as a result of an increase in funding for research and development (R&D) of cephalosporin drugs and antibiotics. For instance, in June 2020, The International Federation of Pharmaceutical Manufacturers and Association established the AMR Action Fund, which will invest more than USD 1 billion over the coming years to support the development of urgently required new antibiotics. The fund is supported by major pharmaceutical companies and also has the support of other stakeholders. It also aims to support the development of market circumstances that will support long-term antibiotic R&D. Similarly, in June 2021, the pharmaceutical company BioVersys, located in Switzerland, received funding of up to USD 4.35 million for its efforts to create a new class of antibiotics.

Additionally, there are also companies involved in the strategic development of new products; for example, in September 2021, Lincoln Pharmaceuticals Limited intends to introduce cephalosporin medicines soon. with the acquisition of the facility in Mehsana, Gujarat, and will invest Rs. 30 crores in the modernization and capacity expansion of the cephalosporin plant. The acquisition and capital expenditures will be paid for out of internal accruals. In February 2020, Shionogi & Co. Ltd announced that FETROJA (cefiderocol) was now available in the United States for patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs). FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.

Hence, all these factors may help the cephalosporin drugs market to witness high growth over the forecast period. However, stringent regulatory approval and side effects associated with cephalosporin restrain the market growth.